GlassScriptPhysician profile
Sean C Pfeffer
NPI 1487690913
$8,774.03
in general payments reported to CMS, 2019-2025
41 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $918 · 2021: $1,813 · 2022: $1,015 · 2023: $1,603 · 2024: $1,551 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,328 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,328.13 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,393.55 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,080.66 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,047.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $926.44 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $753.66 | 2020-2025 | Xifaxan |
| Abbvie INC. | $668.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $428.61 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $395.89 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.13 | 2020-2025 | Jardiance, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $177.54 | 2020-2023 | Belsomra, Segluromet, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $145.14 | 2021-2024 | |
| Exact Sciences Corporation | $134.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $129.57 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.29 | 2019-2024 | Trintellix, Eohilia |
| Idorsia Pharmaceuticals US INC | $116.00 | 2022-2024 | Quviviq |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Pfeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.